![](/img/cover-not-exists.png)
L3â Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients
Versluis, JM, Rozeman, EA, Menzies, AM, Reijers, ILM, Krijgsman, O, Hoefsmit, EP, van de Wiel, BA, Sikorska, K, Bierman, C, Dimitriadis, P, Gonzalez, M, Broeks, A, Kerkhoven, RM, Spillane, AJ, Haanen,Volume:
8
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1136/jitc-2020-itoc7.3
Date:
October, 2020
File:
PDF, 57 KB
2020